Veru Competitors

Veru (NASDAQ:VERU) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Veru and MorphoSys, as reported by MarketBeat.

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Given Veru's stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than MorphoSys.

Profitability

This table compares Veru and MorphoSys' net margins, return on equity and return on assets.

Risk & Volatility

Veru has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Institutional & Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 3.1% of MorphoSys shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Veru and MorphoSys' top-line revenue, earnings per share and valuation.

Veru has higher earnings, but lower revenue than MorphoSys. Veru is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Summary

MorphoSys beats Veru on 7 of the 13 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Veru and Organogenesis, as reported by MarketBeat.

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Organogenesis has a consensus price target of $16.50, suggesting a potential downside of 27.76%. Given Veru's higher possible upside, research analysts clearly believe Veru is more favorable than Organogenesis.

Profitability

This table compares Veru and Organogenesis' net margins, return on equity and return on assets.

Risk & Volatility

Veru has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Institutional & Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 4.6% of Organogenesis shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 57.2% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Veru and Organogenesis' top-line revenue, earnings per share and valuation.

Veru has higher earnings, but lower revenue than Organogenesis. Veru is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Veru (NASDAQ:VERU) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Earnings and Valuation

This table compares Veru and Viela Bio's top-line revenue, earnings per share and valuation.

Veru has higher earnings, but lower revenue than Viela Bio. Veru is trading at a lower price-to-earnings ratio than Viela Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 47.0% of Viela Bio shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 31.5% of Viela Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Veru and Viela Bio, as reported by MarketBeat.

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Viela Bio has a consensus price target of $57.00, suggesting a potential upside of 7.53%. Given Veru's stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than Viela Bio.

Risk & Volatility

Veru has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Profitability

This table compares Veru and Viela Bio's net margins, return on equity and return on assets.

Summary

Veru beats Viela Bio on 8 of the 14 factors compared between the two stocks.

Veru (NASDAQ:VERU) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Veru and OPKO Health's top-line revenue, earnings per share and valuation.

Veru has higher earnings, but lower revenue than OPKO Health. Veru is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 28.5% of OPKO Health shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 40.9% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Veru and OPKO Health, as reported by MarketBeat.

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. OPKO Health has a consensus price target of $9.00, suggesting a potential upside of 115.31%. Given OPKO Health's higher possible upside, analysts plainly believe OPKO Health is more favorable than Veru.

Volatility & Risk

Veru has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

Profitability

This table compares Veru and OPKO Health's net margins, return on equity and return on assets.

Summary

OPKO Health beats Veru on 9 of the 13 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Veru and Taro Pharmaceutical Industries' top-line revenue, earnings per share and valuation.

Taro Pharmaceutical Industries has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Veru and Taro Pharmaceutical Industries, as reported by MarketBeat.

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Taro Pharmaceutical Industries has a consensus price target of $81.00, suggesting a potential upside of 11.22%. Given Veru's higher possible upside, equities analysts plainly believe Veru is more favorable than Taro Pharmaceutical Industries.

Volatility & Risk

Veru has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Profitability

This table compares Veru and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Summary

Taro Pharmaceutical Industries beats Veru on 7 of the 13 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Veru and Corcept Therapeutics' top-line revenue, earnings per share and valuation.

Corcept Therapeutics has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Veru and Corcept Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 16.4% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Veru has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Veru and Corcept Therapeutics, as reported by MarketBeat.

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Corcept Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Given Veru's stronger consensus rating and higher possible upside, equities analysts plainly believe Veru is more favorable than Corcept Therapeutics.

Summary

Corcept Therapeutics beats Veru on 9 of the 14 factors compared between the two stocks.